{"id":402088,"date":"2023-12-27T04:30:13","date_gmt":"2023-12-27T09:30:13","guid":{"rendered":"https:\/\/platohealth.ai\/3-fda-staffers-to-watch-in-2024\/"},"modified":"2023-12-27T19:06:25","modified_gmt":"2023-12-28T00:06:25","slug":"3-fda-staffers-to-watch-in-2024","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/3-fda-staffers-to-watch-in-2024\/","title":{"rendered":"3 FDA staffers to watch in 2024","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
<\/div>\n

W<\/span><\/span>ASHINGTON \u2014 The Food and Drug Administration has a lot on its plate in 2024 with the reorganizations of its food center and the office that inspects FDA-regulated facilities.<\/p>\n

Amid that massive reorganization, the FDA also will lose one of its most influential leaders. Janet Woodcock is retiring<\/a> at the beginning of the year after decades of service. She helped guide some of the most impactful changes to the regulation of medicine and was a steady hand on the agency\u2019s tiller throughout several administrations.<\/p>\n

\n

advertisement<\/p>\n<\/div>\n

The agency also will likely need to decide whether to take action on the regulation of lab-developed diagnostics, and it\u2019s getting serious about making clinical trials more representative of the people that drugs treat.<\/p>\n

\n
\n
\n

\n\t\t\t\t\t\tGet unlimited access to award-winning journalism and exclusive events.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n<\/p><\/div>\n<\/p><\/div>\n